Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies -
| BRIBF Stock | USD 0.13 0.00 0.00% |
Roughly 56% of Brii Biosciences' investor base is looking to short. The analysis of overall sentiment of trading Brii Biosciences Limited pink sheet suggests that many investors are alarmed at this time. The current market sentiment, together with Brii Biosciences' historical and current headlines, can help investors time the market. In addition, many technical investors use Brii Biosciences stock news signals to limit their universe of possible portfolio assets.
Brii Biosciences pink sheet news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Brii daily returns and investor perception about the current price of Brii Biosciences Limited as well as its diversification or hedging effects on your existing portfolios.
Brii |
Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies
Read at news.google.com
 |
Brii Biosciences Fundamental Analysis
We analyze Brii Biosciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Brii Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Brii Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Z Score
Z Score Comparative Analysis
Brii Biosciences is currently under evaluation in z score category among its peers. Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
Brii Biosciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Brii Biosciences pink sheet to make a market-neutral strategy. Peer analysis of Brii Biosciences could also be used in its relative valuation, which is a method of valuing Brii Biosciences by comparing valuation metrics with similar companies.
Peers
Brii Biosciences Related Equities
| AVTX | Avalo Therapeutics | 15.02 | ||||
| INZY | Inozyme Pharma | 12.12 | ||||
| ZVSA | ZyVersa Therapeutics | 7.86 | ||||
| HOOK | Hookipa Pharma | 7.84 | ||||
| SONN | Sonnet Biotherapeutics | 7.60 | ||||
| ETNB | 89bio | 3.18 | ||||
| MIRM | Mirum Pharmaceuticals | 3.06 | ||||
| AXSM | Axsome Therapeutics | 1.58 | ||||
| INCY | Incyte | 1.05 | ||||
| SRPT | Sarepta Therapeutics | 0.70 | ||||
| BNTC | Benitec Biopharma | 0.28 | ||||
| AKRO | Akero Therapeutics | 0.00 | ||||
| DAWN | Day One | 0.80 | ||||
| TERN | Terns Pharmaceuticals | 0.86 | ||||
| ACAD | ACADIA Pharmaceuticals | 1.31 | ||||
| CABA | Cabaletta Bio | 2.31 | ||||
| ALZN | Alzamend Neuro | 2.54 | ||||
| VRAX | Virax Biolabs | 3.27 | ||||
| XFOR | X4 Pharmaceuticals | 8.52 | ||||
| CDIO | Cardio Diagnostics | 11.00 |
Complementary Tools for Brii Pink Sheet analysis
When running Brii Biosciences' price analysis, check to measure Brii Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brii Biosciences is operating at the current time. Most of Brii Biosciences' value examination focuses on studying past and present price action to predict the probability of Brii Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Brii Biosciences' price. Additionally, you may evaluate how the addition of Brii Biosciences to your portfolios can decrease your overall portfolio volatility.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |